Lisa La on Areas of Interest Within Multiple Myeloma
The clinical researcher discussed areas of multiple myeloma which she believes deserve further assessment.
In an interview with CancerNetwork®, Lisa La, director of clinical research in the Center for Cancer Care at White Plains Hospital, spoke about what areas of multiple myeloma she believes deserve further evaluation.
Transcription:
The last 5 or 6 years have really focused on heavily treated relapsed/refractory myeloma patients. And I think it's because a lot of the times these patients don't really have any options left, right? You've done all of the concoctions of different combinations of chemotherapy and you've given them multiple transplants in hopes to prolong their quality of life and also their life in general.
So, I think that it would be interesting to see if we can look into the earlier stages of myeloma, right, perhaps looking more at smoldering myeloma patients or newly diagnosed patients, maybe we can find some sort of treatment that could really nip it in the bud there instead of waiting until it becomes heavily pretreated relapsed/refractory myeloma. I know there's a lot of complications with smoldering and newly diagnosed myeloma, you run into a lot of insurance issues and the budgets for those studies seem to be much more expensive, and so on, so forth. But I think if we can catch it earlier on, I think that would be an interesting research area to look into. And also, there's a lot of excitement about translational research in myeloma, looking at different targets, looking at possibly personalized medicine. I know that's been in the talks for some time, but I think that that'd be interesting as well.
Network Meta-Analysis of Treatment Regimens for Relapsed/Refractory Multiple Myeloma
March 24th 2020The researchers indicated that the results could provide additional guidance for the decision-making process when clinicians are deciding on the most appropriate regimen for relapsed and/or refractory multiple myeloma.
Recommendations for Under-Representation of African Americans in Multiple Myeloma
February 14th 2020In a workshop conducted by the FDA and the AACR, working groups came together to address disparities in the representation of African Americans in multiple myeloma clinical trials and to create a set of recommendations in an attempt resolve them.
